| Apceth GmbH & Co. KG Patent applications |
| Patent application number | Title | Published |
|---|
| 20120087901 | Engineered Mesenchymal Stem Cells and Methods of Using Same to Treat Tumors - This invention provides a method for treating a subject afflicted with a tumor using genetically modified mesenchymal stem cells, wherein each genetically modified mesenchymal stem cell contains an exogenous nucleic acid comprising (i) a cytotoxic protein-encoding region operably linked to (ii) a promoter or promoter/enhancer combination, whereby the cytotoxic protein is selectively expressed when the genetically modified mesenchymal stem cells come into proximity with the tumor's stromal tissue. This invention further provides genetically modified mesenchymal stem cells for use in this method. | 04-12-2012 |
| 20110183414 | Expansion Medium for CD34-Negative Stem Cells - This invention provides a cell growth medium comprising (a) a human platelet lysate free of solid matter greater than 0.22 μm in diameter, wherein the lysate constitutes from 2% to 15% of the total volume of the cell growth medium; (b) a human fresh frozen plasma (FFP) filtrate free of solid matter greater than 0.22 μm in diameter, wherein the FFP filtrate constitutes from 1% to 10% of the total volume of the cell growth medium; (c) heparin at a concentration of from 0 U/ml to 10 U/ml of the cell growth medium; (d) L-glutamine at a concentration of from 0.5 mM to 10 mM; and (e) a serum-free, low glucose medium suitable for mammalian cell growth, wherein the serum-free, low glucose medium constitutes from 75% to 97% of the total volume of the cell growth medium, and may contain the L-glutamine of part (d); wherein the cell growth medium permits the expansion of human CD34 | 07-28-2011 |
| 20090041735 | CD34 Stem cell-related methods and compositions - This invention provides novel stem cell-based methods for treating a number of conditions. These methods employ CD34 | 02-12-2009 |
